Kornimate/medical-research-clean huggingface dataset:
energy dense formula to people living in old peoples home

Conditions: Protein-Energy Malnutrition; Anorexia; Weight Change

Summary: dietary intake in frail elderly is often lower than estimated needs due to the combined effects of the anorexia of ageing, frailty and the presence of acute and chronic disease. the objectives of the present study are to assess the effects of an oleic acid rich formula fortified with micronutrients on energy intake, vitamin- and mineral status, muscle strength and mobility. the investigators have recently performed a similar study in an acute ward setting without micronutrients.

malnutrition has been reported to be present in up to 55% of acutely hospitalised elderly and in one third of people living in assisted accommodation. frail elderly with poor appetite are at risk for malnutrition. rebecca stratton et al have reviewed effects of oral nutritional supplements (ons) in elderly hospital patients and key findings in hospital trials were that ons can improve intakes of energy, protein and micronutrients without substantially reducing food intake which may lead to weight gain or attenuate weight loss. calogen extra is a fat emulsion containing 400 kcal/100 ml, based on canola and sunflower-oil which has a good fat composition. moreover it contains around 30 % of recommended micronutrients and 5g protein/100 ml. it has potentially positive effects on energy intake, fatty acid profile and constipation. the investigators have recently performed a clinical trial in geriatric patients in an acute-ward setting to evaluate the effects of a similar fat emulsion, calogen, without micronutrients. the investigators could conclude that this fat emulsion based on mufa and pufa distributed three times daily at medication rounds may have positive effects on weight, appetite and serum lipids. moreover the approach was well accepted by patients and nurses. the intervention period was very short (median 8 days) therefore the investigators plan to perform a study with a similar design, for a longer period of time, in a group of elderly living in old peoples home.

Eligibility criteria:
inclusion criteria: * \>65 years old * mini nutritional assessment-short form (mna-sf)score \< 12 points * able to give informed consent. exclusion criteria: * pancreatitis * fat malabsorption, non-consent for participation. * subjects that have calogen will be excluded.

Keywords: malnutrition oleic-acid micronutrient supplement old peoples home
rollover study to evaluate histological results of radiofrequency device treatments on the flanks

Conditions: Skin Laxity

Summary: the purpose of this study is to evaluate histological results of the treatments with the tempsure firm handpiece on the flanks performed in the cyn20-firm-lipo study.

up to 10 subjects will be enrolled at up to 3 study centers. subjects will receive 2 biopsies, 1 biopsy in the treatment area (the flanks) and 1 biopsy outside of the treatment area to serve as a control.

Eligibility criteria:
inclusion criteria: • subject has completed their participation in the cyn20-firm-lipo study. exclusion criteria: * the subject has not had any other treatment in the treatment area after their involvement in the cyn20-firm-lipo study. * the subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
effect of growth hormone in children with growth hormone deficiency

Conditions: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Growth Disorder; Idiopathic Short Stature

Summary: this trial is conducted in the united states of america (usa). the purpose of the trial is to compare the effect of norditropin® using different dosing regimens in children suspected of growth hormone deficiency.


Eligibility criteria:
inclusion criteria: * clinically suspected ghd * height \< -2.0 sds * serum igf-i less than or equal to -1.0 sds * bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls. * puberty tanner stage i exclusion criteria: * previous use of growth hormone * growth retardation attributable to causes other than ghd (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.) * intrauterine growth retardation: birth weight \< 3rd percentile. * administration of other growth-altering medications. * evidence of any malignancy or intracranial tumors.
double blind study of thymopentin effects on hiv-1 infectivity of blood mononuclear cells and semen in hiv infected patients

Conditions: HIV Infections

Summary: examine the ability of timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with hiv who do not yet have aids.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * aerosolized pentamidine. patients must have the following: - seropositive for hiv-1 (elisa assay) confirmed by western blot. hiv-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' peripheral blood monocytes (pbmc) on two separate occasions. voluntarily sign consent. patients with hiv "wasting syndrome" are included. prior medication: allowed: * aerosolized pentamidine. exclusion criteria co-existing condition: patients with the following are excluded: * aids as defined by the cdc (except for those with hiv "wasting syndrome"). * significant hepatic disease. * thrombocytopenia. * hypersensitivity to thymopentin. * hemophilia a or b or other hematologic disorders requiring current or previous administration of blood products. * abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. patients with the following are excluded: * aids as defined by the cdc (except for those with hiv "wasting syndrome"). * significant hepatic disease. * thrombocytopenia. * hypersensitivity to thymopentin. * hemophilia a or b or other hematologic disorders requiring current or previous administration of blood products. * abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. prior medication: excluded within 30 days of study entry: * immunomodulatory or experimental therapy. * excluded within 90 days of study entry: * zidovudine (azt). intravenous drug abuse.

Keywords: semen thymopentin leukocytes, mononuclear hiv seropositivity aids-related complex
infliximab in treating cancer-related fatigue in postmenopausal women who have undergone treatment for breast cancer

Conditions: Breast Cancer; Fatigue

Summary: rationale: infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. purpose: this phase ii trial is studying how well infliximab works in treating cancer-related fatigue in postmenopausal women who have undergone treatment for stage 0, stage i, or stage ii breast cancer.

objectives: * determine the association between the body's immune system and energy, sleep, mood, and other symptoms in postmenopausal women who have undergone treatment for stage 0-ii breast cancer. * determine whether treatment with infliximab affects energy and immune function in these patients. outline: patients receive infliximab iv over 2 hours. patients complete a diary twice daily for 14 days before and for 14 days after infliximab administration to assess fatigue and other symptoms, including mood, pain, and sleep. after completion of study treatment, patients are followed at 2 weeks and then monthly for 3 months. projected accrual: a total of 10 patients will be accrued for this study.

Eligibility criteria:
inclusion criteria: * women who report elevated fatigue following cancer diagnosis and treatment exclusion criteria: * women who have medical conditions that may affect the immune system or are associated with baseline fatigue syndrome, and/or who use medications that affect the immune system or fatigue. * women with major affective disorders and those with sleep or pain disorders. * presence of medical conditions that may but subject at undue risk for experimental procedures. * chronic or recurring infections, symptoms of chronic heart failure, demyelinating disorders, and those taking immunosuppressive medications. * neoplastic disease other than primary breast cancer * compromised cardiovascular function * insulin-dependent diabetes * neurological disorder * peripheral neuropathy * pregnancy * use of psychotropic medications within 2 weeks of screening * abnormal screening laboratory findings (i.e., creatinine \> 1.4mg%; anemia; abnormal thyroid hormone; hematuria; elevated liver function tests, low protein or albumin; fasting glucose \>120mg%; elevated fti or tsh; positive tb screening, hiv screening or hepatitis c). * smokers

Keywords: stage i breast cancer stage ii breast cancer breast cancer in situ fatigue
tau pet imaging in atypical dementias

Conditions: Primary Progressive Aphasia With Suspected Alzheimer's Disease

Summary: the goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with primary progressive aphasia, using pet protocol with f-av-1451 (trade name av-1451) and to systematically document the extent and location of tau pathology in ppa patients in vivo using the same techniques.


Eligibility criteria:
inclusion criteria: * must have primary progressive aphasia exclusion criteria: * pregnancy * breastfeeding * receiving radiation clinically
dynamic orthotic garment in diplegic cerebral palsy

Conditions: Diplegic Cerebral Palsy

Summary: this study aims to evaluate the effectiveness of dynamic orthotic garment (thera togs) on foot pressure distribution, postural control, functional performance and endurance in children with spastic diplegic cerebral palsy (cp). methods: forty children with spastic diplegic cp, with ages ranging from 8 to 10 years, will be assigned randomly into two groups. the control group will receive the conventional physical therapy, whereas the study group will receive the same program as the control group in addition to thera togs. measurement of foot pressure distribution will be performed using a pressure platform, postural control will be evaluated using the trunk control measurement scale trunk position sense pediatric berg balance scale, endurance will be assessed using six-minute walk test (6mwt)

this study aims to evaluate the effectiveness of dynamic orthotic garment (thera togs) on foot pressure distribution, postural control, functional performance and endurance in children with spastic diplegic cerebral palsy (cp). methods: forty children with spastic diplegic cp, with ages ranging from 8 to 10 years, will be assigned randomly into two groups. the control group will receive the conventional physical therapy, whereas the study group will receive the same program as the control group in addition to thera togs. measurement of foot pressure distribution will be performed using a pressure platform, postural control will be evaluated using the trunk control measurement scale ,trunk position sense , pediatric berg balance scale, endurance will be assessed using six-minute walk test (6mwt)

Eligibility criteria:
inclusion criteria: * children with cp who have toe-in gait and had grade 1+ to 2 degree of spasticity according to the modified ashworth scale (mas) \[32\]. in addition to score i and ii on gross motor function classification system (gmfcs) scores \[33\]. as well as the child is required to be able to stand and walk independently. exclusion criteria: * children who have impaired hearing or vision, previous lower limb surgery or botulinum injections of the lower limb muscles within the preceding 6 months will be excluded from the study.

Keywords: theratog postural control cerebral palsy
fmt for ms patients

Conditions: Multiple Sclerosis

Summary: this is a placebo-controlled, double-blinded, randomized trial design, whereby all patients are eligible to start an injectable therapy, and then randomized to either placebo or fmt for approximately 1 year.

fecal microbiome transplants: patients will undergo pretreatment with amoxicillin/clavulinate (or matched placebo) for 5 days followed by a bowel cleanse with peglyte. patients will undergo allogeneic or autologous fecal transplants. patients will be dosed with fmt oral capsules approximately 48 hours after antibiotic treatment has stopped. following the fmt capsule treatment on day 1, patients will be administered a repeat oral capsule or placebo dose at 3 weeks. oral omeprazole or omeprazole placebo will be given 1 hour prior to the baseline and 3 week dose. this will be done to ensure full engraftment of the transplant. participants will be seen at baseline, 3 weeks, 6 weeks, 3 months, 6 months and 12 months. a series of neurological tests will be performed for safety measures. in addition to this, mris will be completed at baseline, 6 weeks and 12 months. blood, urine and stool samples will also be collected for data analysis and safety measures.

Eligibility criteria:
inclusion criteria: * 18 - 55 years of age * have an expanded disability status scale (edss) of \< 6 * have a diagnosis of relapsing multiple sclerosis * have evidence of radiographic activity within the 12 months on mri (new/enlarging t2 lesion or gadolinium enhancing lesion) * eligible to start/starting an injectable dmt * not on a dmt currently and/or not on a dmt in last 6 months * ability to swallow capsules exclusion criteria: * unable to provide informed consent * does not pass the standard mri screening questionnaire * other disease that can affect gi permeability (such as inflammatory bowel disease, crohn's disease, ulcerative colitis, indeterminate colitis or microscopic colitis, celiac disease) * expected requirement for antibiotics within 3 months (chronic suppressive therapies, elective prosthetic joint insertion) * toxic megacolon, small bowel ileus * penicillin allergy * omeprazole allergy
vitamin d status among infertile women in sweden

Conditions: Infertility, Female; Vitamin D Deficiency

Summary: the goal of this prospective cohort study is to learn about the overall and seasonal prevalence of vitamin d insufficiency and its determinants in a population of women with infertility who will go through in vitro fertilization in sweden. the main questions it aims to answer are: * what is the prevalence of vitamin d insufficiency? * what are the determinants of this insufficiency? participants will be asked to complete a questionnaire validated for dietary assessment of vitamin d intake and sun exposure habits and they will leave a blood sample for measurement of 25(oh)d concentration. researchers will compare the in vitro fertilization outcomes between women with vitamin d insufficiency and sufficiency to see if there is any difference.


Eligibility criteria:
inclusion criteria: * women aged 18-38 years, who will go through in vitro fertilization for infertility. exclusion criteria: * women who will go through pre-implantation genetic testing * women who will go through sperm- or oocyte donation treatment * fertility preservation cycles
the effects of l-tyrosine on 24 hour blood pressure and heart rate in parkinson's disease

Conditions: Blood Pressure

Summary: the investigators are observing the effects 2,000 mg of l-tyrosine will have on 24 hour blood pressure fluctuations in individuals with parkinson's disease.

we will be monitoring 24 hour ambulatory bp and hr in subjects with pd on 3 separate visits. the first visit will be without an intervention to establish a baseline of 24 hour bp fluctuations. one week later the subject will be given either l-tyrosine (2,000 mg) with b6 (10 mg) or a sugar pill. we will monitor 24 hour bp and hr after supplementation. one week later the subject will repeat the same procedures with either supplement or placebo. this is a total of 3 visits with 24 hour ambulatory bp and hr monitoring.

Eligibility criteria:
inclusion criteria: 1. all subjects must have a diagnosis of pd by a licensed neurologist according to the uk parkinson's disease society brain bank clinical diagnostic criteria (ukpdbb).(goetz, 2010) the ukpdbb is a 3 step diagnostic tool which defines inclusion and exclusion criteria for diagnosing pd 2. between 35 and 79 years of age 3. mentally able to participate in the study exclusion criteria: 1. pregnancy 2. any person who is currently taking amino acid supplements. 3. any history of myocardial infarction, stent, or cabg 4. phenylketonurics 5. untreated hypertension
assessment of the effect of captopril versus combination of captopril and pentoxifylline on reducing proteinuria in type 2 diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: diabetic nephropathy is the most common cause of esrd and has a great impact on mortality and morbidity of diabetic patients. despite renoprotective effect of ace inhibitors in diabetic patients they can not hinder the progression of renal disease completely. pentoxifylline as a tnfa blocker may hinder progression of diabetic nephropathy in combination of captopril.

diabetic nephropathy is the most common cause of esrd and has a great impact on mortality and morbidity of diabetic patients. despite renoprotective effect of ace inhibitors in diabetic patients they can not hinder the progression of renal disease completely. tnfa is a cytokine that is a target for medical therapy in diabetic nephropathy. in this study the effect of captopril on overt diabetic nephropathy compared to effect of combination of captopril and an antitnfa drug ( pentoxifylline).

Eligibility criteria:
inclusion criteria: 1. absence of kidney or urinary tract disease 2. absence of high blood pressure or controlled blood pressure (≤140/90) with medication other than ace inhibitors and/or non dihydropyridine calcium channel blockers 3. a well controlled blood sugar level (hba1c≤7.5%) 4. adhering to the diet protocol for patients with renal disease exclusion criteria: 1. nyha functional class iii, iv 2. valvular heart disease 3. unstable angina, myocardial infarction, cerebrovascular accidents 4. psychiatric disease 5. prior allograft kidney transplant 6. acute illness 7. infectious disease including urinary tract infection 8. leukocytosis or any febrile illness at enrollment 9. prior history or development of any form of malignancy 10. history of alcohol or drug abuse or smoking 11. pregnancy 12. need for surgery during the study 13. allergy to derivatives of methyl xanthines 14. current pentoxyphilline use

Keywords: diabetes proteinuria pentoxifylline
dissecting the pattern of nodal spread in post-neoadjuvant pancreatoduodenectomy

Conditions: Pancreas Cancer; Pancreatic Adenocarcinoma

Summary: there has been long-standing debate about nodal dissection in pancreatoduodenectomy (pd) for pancreatic ductal adenocarcinoma (pdac), with most studies examining the value of nodal yields, number of metastatic nodes and spatial location of metastases being conducted in the upfront surgery setting. with increasing use of a chemotherapy-first approach even in early stage pdac, the validity of nodal parameters in post-treatment pd has been brought into question due to therapy-induced lymph node (ln) shrinkage. however, the available information is based on retrospective data or administrative registries, which only considered the number of examined and metastatic nodes, without detailed information regarding the dissection protocol and the influence of nodal metastases location. back in 2013, corresponding to the standard lymphadenectomy definition release by the international study group of pancreatic surgery (isgps) and the diffusion of multi-agent chemotherapy regimens, an institutional, station-based nodal dissection protocol was established for post-neoadjuvant pd. the aim was to investigate whether the pattern of metastatic spread within the nodal basin is a superior quality metric for prognosis relative to the count-based classification system.


Eligibility criteria:
inclusion criteria: * post-neoadjuvant pancreatoduodenectomy for localized pancreatic ductal adenocarcinoma. exclusion criteria: * oligometastatic disease * upfront pancreatectomy * incomplete lymphadenectomy * macroscopically incomplete resections * rare variants of pancreatic cancer

Keywords: pancreatoduodenectomy lymphadenectomy lymph nodes pancreatic cancer
prevalence of pituitary incidentaloma in relatives of patients with pituitary adenoma

Conditions: Pituitary Tumor

Summary: the purpose of the study is to determine genetic links among blood-relatives and between spouses of patients with pituitary tumors.

the purpose of the family study is to investigate the genetic basis for the development of pituitary tumors by assessing the prevalence of pituitary tumors in relatives of probands with the disease as compared to the prevalence in unrelated spouses sharing a similar environment.

Eligibility criteria:
inclusion criteria: * patients harboring secretory or non-secretory adenomas and/or siblings and/or spouses exclusion criteria: * patient without consenting siblings and/or siblings and/or spouses

Keywords: pituitary adenoma tumor acromegaly prolactinoma cushing's
erbium vaginal laser for the treatment of stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: two arms of women who suffer from clinical stress urinary incontinence. women will be divided randomly into two arms. one arm will be treated with vaginal erbium laser and the second with sham laser, three treatments each. follow up will be done 6 and 12 months after the last treatment.

examine the efficacy of vaginal erbium laser treatment for stress urinary incontinence (sui) in compare to placebo. plenty of women suffer from sui. it is a condition in which involuntary urine leakage occurs during exercise. this condition affects about 40% of all women and causes huge disturbance to daily life. there are plenty of risk factors, such as age, obesity and parity. we assume that the pathophysiology is related to hypermobility of the urethra due to damage to the surrounding tissue. the treatment options vary from surgical interventional to conservative, each treatment has its own success rate and risk factors. an attempt to find effective treatment option has been made. the use of laser for various gynecologic conditions are at rise. erbium type laser works on the lamina propria layer and causes rejuvenation probably by strengthening collagen structures and creating new ones. the efficacy and safety of vaginal laser therapy has been proven already, but in the field of sui the numbers in each study were low and there was no control group. in this study we desire to examine the effect of vaginal erbium treatment on sui in compare to placebo. this is a randomized single blind control trial. 40 women will be included in the research group and 40 in the placebo group. women will be assigned randomly to each group. they will be treated with vaginal laser probe, three treatments 4 weeks apart. follow up visits will be performed 3, 6, and 12 months after the first treatment. effectiveness evaluation will be done by physical urodynamic examination before treatment and 6 month after finishing, by 24 hours pad test' cough test and by fulfilling questionnaires- 1. the urogenital distress inventory (udi6) 2. the female sexual function index (fsfi)

Eligibility criteria:
inclusion criteria: women above 18 with sui - exclusion criteria: 1. recurrent pelvic inflammatory disease 2. vaginal operation in the previous year 3. women with abnormal uterine bleeding 4. women with diagnosed genital herpes infection 5. any concurrent lower genital tract infection -